In This Section

AACR Science Series at the FDA

The AACR Science Series at the FDA sessions began in July 2012. This series brings scientific leaders to the FDA campus to present cutting-edge advances in cancer biology to FDA scientific review staff and to foster the development of relationships between FDA reviewers and external scientific experts. Since January 2013, the AACR has been offering CME credits for these sessions.”

T Cells as the Future of Cancer Immunotherapy, January 22, 2021

Antoni Ribas, MD, PhD, Director, Tumor Immunology Program, University of California Los Angeles Jonsson Comprehensive Cancer Center; AACR President (2020-2021) CME Information

Highlights of the AACR Annual Meeting 2019, July 26, 2019

Elizabeth M. Jaffee, MD, Deputy Director, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Dana and Albert “Cubby” Broccoli Professor of Oncology; AACR President (2018-2019)

Epigenetics, Dec. 7, 2015

Stephen B. Baylin, MD, Professor of Oncology and Medicine, Sidney Kimmel Comprehensive Cancer Center

Charles W.M. Roberts, MD, PhD, Director and Executive Vice President, Comprehensive Cancer Center, St. Jude Children’s Research Hospital

Highlights of the AACR Annual Meeting 2015, July 27, 2015

Carlos L. Arteaga, MD, Associate Director for Clinical Research; Director, Breast Cancer Research Program; and Director, Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center; AACR President (2014-2015)

Lewis C. Cantley, PhD, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College

Novel Approaches to Rational Drug Design, Dec. 12, 2014

Nathanael Gray, PhD, Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Cancer Biology at Dana-Farber Cancer Institute

Lawrence Marnett, PhD, Director of the A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Mary Geddes Stahlman Professor of Cancer Research, Vanderbilt University

Highlights of the AACR Annual Meeting 2014, July 21, 2014

Charles L. Sawyers, MD, Chairman, Human Oncology and Pathogenesis Program; Marie-Josee and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center; AACR President (2013-2014)

Scott W. Lowe, PhD, Chair of the Cancer Biology and Genetics Program and the Geoffrey Beene Cancer Research Center; Howard Hughes Medical Institute Investigator at Memorial Sloan Kettering Cancer Center

Novel Non-Invasive Techniques to Detect and Monitor Tumors, March 10, 2014

Victor E. Velculescu, MD, PhD, Director of Cancer Genetics, Ludwig Center at Johns Hopkins and Co-director of Cancer Biology, Johns Hopkins Kimmel Cancer Center

Daniel A. Haber, MD, PhD, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology at Harvard Medical School

Targeting Metabolic Pathways in Hematologic Malignancies and Solid Tumors, November 4, 2013

Kenneth C. Anderson, MD, PhD (hon), Kraft Family Professor of Medicine, Harvard Medical School; Medical Director, Kraft Family Blood Center, Dana-Farber Cancer Institute; and Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute

Lewis C. Cantley, PhD, Director, Cancer Center, Weill Cornell Medical College of Cornell University

Highlights of the AACR Annual Meeting 2013, July 29, 2013

Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee

Jeffrey A. Engelman, MD, PhD, Director, Center for Thoracic Cancers at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School

Rational Strategies for Developing BRAF Inhibitors: Rational Combinations; Overcoming Resistance, Jan. 14, 2013

Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee

Gideon E. Bollag, PhD, CEO, Research, Plexxikon Inc.

Immunotherapies, Oct. 1, 2012

James P. Allison, PhD, Professor and Chair, The University of Texas MD Anderson Cancer Center; Department of Immunology in the Division of Basic Science Research, Deputy Director, David H. Koch Center for Applied Research in Genitourinary Cancers, Department of Genitourinary Medical Oncology and Research; Investigator, Howard Hughes Medical Institute

David L. Porter, MD, Jodi Fisher Horowitz professor in leukemia care excellence; Director, Blood and Marrow Transplantation, Hospital of the University of Pennsylvania

Highlights of the AACR Annual Meeting 2012, July 23, 2012

Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee

Benjamin G. Neel, PhD, MD, director of research of the Princess Margaret Cancer Centre, University Health Network